share_log

Leerink Partners Upgrades ARS Pharmaceuticals to Outperform, Raises Price Target to $18

Benzinga ·  Mar 5 07:11

Leerink Partners analyst Roanna Ruiz upgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Market Perform to Outperform and raises the price target from $6 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment